氯-IB-MECA结构式
|
常用名 | 氯-IB-MECA | 英文名 | 2-CL-IB-MECA |
|---|---|---|---|---|
| CAS号 | 163042-96-4 | 分子量 | 544.731 | |
| 密度 | 2.0±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C18H18ClIN6O4 | 熔点 | 209 °C | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS07 |
信号词 | Warning |
氯-IB-MECA用途Namodenoson (CF-102) 是一个选择性的 A3 adenosine 受体的激动剂,选择性分别是A1,A2的2500到1400倍。 |
| 中文名 | 1-[2-氯-6-[[(3-碘苯基)甲基]氨基]-9h-嘌呤-9-基]-1-脱氧-N-甲基-beta-d-呋喃核糖酰胺 |
|---|---|
| 英文名 | (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide |
| 英文别名 | 更多 |
| 描述 | Namodenoson (CF-102) 是一个选择性的 A3 adenosine 受体的激动剂,选择性分别是A1,A2的2500到1400倍。 |
|---|---|
| 相关类别 | |
| 靶点 |
Ki:0.33 nM (A3 adenosine receptor)[1][2]. |
| 体外研究 | 在星形胶质细胞谱系的人ADF细胞中,100nMNModenodenoson(2-Cl-IB-MECA)引起细胞骨架的显着重组,具有应力纤维和许多细胞突起的外观。高浓度的Namodenoson(2-Cl-IB-MECA)直接引起Ca2 +的流入[2]。 |
| 体内研究 | 静脉内施用200μg/ kg Namodenoson(2-Cl-IB-MECA)导致短暂的低血压,伴随着血浆组胺浓度增加50-100倍。施用第二剂量的Namodenoson(2-Cl-IB-MECA)未引起任何血液动力学效应[1]。 |
| 参考文献 |
| 密度 | 2.0±0.1 g/cm3 |
|---|---|
| 熔点 | 209 °C |
| 分子式 | C18H18ClIN6O4 |
| 分子量 | 544.731 |
| 精确质量 | 544.012268 |
| PSA | 134.42000 |
| LogP | 3.14 |
| 外观性状 | 固体;White to Almost white powder to crystal |
| 折射率 | 1.814 |
| 储存条件 | 0-10°C;避免加热 |
| 符号 |
GHS07 |
|---|---|
| 信号词 | Warning |
| 危害声明 | H315-H319-H335 |
| 警示性声明 | P261-P305 + P351 + P338 |
| 个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
| 危害码 (欧洲) | Xi: Irritant; |
| 风险声明 (欧洲) | R36/37/38 |
| 安全声明 (欧洲) | S26 |
| 危险品运输编码 | NONH for all modes of transport |
| 海关编码 | 2934999090 |
|
~70%
氯-IB-MECA 163042-96-4 |
| 文献:Kim; Ji; Siddiqi; Olah; Stiles; Jacobson Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3614 - 3621 |
|
~%
氯-IB-MECA 163042-96-4 |
| 文献:Journal of Medicinal Chemistry, , vol. 37, # 21 p. 3614 - 3621 |
|
~%
氯-IB-MECA 163042-96-4 |
| 文献:Journal of Medicinal Chemistry, , vol. 37, # 21 p. 3614 - 3621 |
|
~%
氯-IB-MECA 163042-96-4 |
| 文献:Journal of Medicinal Chemistry, , vol. 37, # 21 p. 3614 - 3621 |
|
~%
氯-IB-MECA 163042-96-4 |
| 文献:Journal of Medicinal Chemistry, , vol. 37, # 21 p. 3614 - 3621 |
|
~%
氯-IB-MECA 163042-96-4 |
| 文献:US2005/256143 A1, ; Page/Page column Sheet 1 of 3 ; |
| 氯-IB-MECA上游产品 4 | |
|---|---|
| 氯-IB-MECA下游产品 0 | |
| 海关编码 | 2934999090 |
|---|---|
| 中文概述 | 2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途 |
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
Cancer Chemother. Pharmacol. 74(4) , 847-60, (2014) Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the deadliest form of skin cancer. Melanoma progression is associated with the abrogation of normal control... |
|
|
Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus.
J. Neurosci. 17 , 607-614, (1997) The adenosine A3 receptor is expressed in brain, but the consequences of activation of this receptor on electrophysiological activity are unknown. We have characterized the actions of a selective aden... |
|
|
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Cell Death Dis. 5 , e1539, (2014) Therapies that target the signal transduction and biological characteristics of cancer stem cells (CSCs) are innovative strategies that are used in combination with conventional chemotherapy and radio... |
| CF102 |
| CI-IB-MECA |
| 2-Cl-IB-Meca |
| Cl-IB-MECA |
| Namodenoson |
| 2-chloro-IB-MECA |
| (2S,3S,4R,5R)-5-{2-Chloro-6-[(3-iodobenzyl)amino]-9H-purin-9-yl}-3,4-dihydroxy-N-methyltetrahydro-2-furancarboxamide (non-preferred name) |
| UNII:Z07JR07J6C |
| CF-102 |
| CF-102(2-Cl-IB-MECA) |